Skip to main content

Table 2 Univariate and multivariate analyses in patients received IC + RT(n = 88) or CCRT(n = 44) after propensity score matching

From: Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis

  OS CSS LRFFS DFFS
HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Univeriate parameter
 Age Continuous variable 1.051(0.977–1.131) 0.185 1.046 (0.967–1.132) 0.261 0.892(0.737–1.079) 0.239 1.044(0.945–1.154) 0.399
 Gender male vs. female 1.301(0.590–2.869) 0.514 1.119(0.504–2.487) 0.782 2.131(0.277–16.397) 0.467 1.434(0.433–4.751) 0.555
 T-stage T1-2 vs. T3-4 0.907(0.496–1.659) 0.752 0.974(0.518–1.833) 0.936 2.725(0.915–8.115) 0.072 0.984(0.418–2.320) 0.971
 N-stage N0-1vs. N2-3 0.902(0.538–1.512) 0.902 1.087(0.628–1.883) 0.765 1.200(0.403–3.570) 0.744 0.763(0.361–1.614) 0.479
 Clinical stage I-II vs. III-IV 0.805(0.291–2.228) 0.805 0.929(0.334–2.580) 0.887 2.088(0.462–9.430) 0.338 0.436(0.059–3.209) 0.415
 NP dose (Gy) Continuous variable 1.007(0.930–1.090) 0.862 1.002(0.921–1.090) 0.960 0.925(0.808–1.058) 0.253 1.042(0.923–1.175) 0.510
 LN dose (Gy) Continuous variable 1.023(0.980–1.068) 0.292 1.021(0.975–1.068) 0.380 0.946(0.871–1.027) 0.187 1.057(0.993–1.125) 0.083
 RT Days Continuous variable 1.006(0.981–1.032) 0.623 1.010(0.984–1.037) 0.451 0.954(0.887–1.026) 0.203 1.013(0.977–1.050) 0.493
 Treatment group IC + RT vs. CCRT 0.717(0.421–1.220) 0.220 0.682(0.388–1.198) 0.183 0.747(0.244–2.284) 0.609 1.709(0.693–4.218) 0.245
 Cranial nerve involvement absent vs. present 0.781(0.354–1.726) 0.542 0.663(0.298–1.476) 0.314 0.581(0.128–2.628) 0.481 0.657(0.228–1.896) 0.437
 Basicranial Bone involvement absent vs. present 0.553(0.329–0.929) 0.025 0.558(0.321–0.969) 0.038 0.784(0.263–2.341) 0.663 0.712(0.339–1.497) 0.371
 Family history absent vs. present 1.142(0.413–3.155) 0.798 1.349(0.420–4.335) 0.615 22.74(0.003–25.96) 0.494 0.655(0.197–2.171) 0.489
Multivariate parametera
 Treatment group IC + RT vs. CCRT 0.706(0.412–1.208) 0.204 0.708(0.402–1.246) 0.231 0.696(0.207–2.342) 0.558 1.627(0.658–4.023) 0.292
 Basicranial Bone involvement absent vs. present 0.553(0.329–0.929) 0.025 0.558(0.321–0.969) 0.038 0.246(0.044–1.382) 0.111 0.760(0.337–1.715) 0.508
 T-stage T1-2 vs. T3-4 1.347(0.638–2.842) 0.435 1.490(0.675–3.289) 0.324 6.833(1.224–38.148) 0.028 1.355(0.481–3.819) 0.565
  1. CI confidence interval, IC + RT induction chemotherapy followed by radiotherapy, CCRT concurrent chemoradiotherapy, NP nasopharynx, LN lymph node
  2. aOther covariates not shown (P > 0.05)